Clinical Scorecard: Efficacy and Safety of 8 mg Aflibercept in PULSAR Extension
At a Glance
| Category | Detail |
|---|---|
| Condition | Neovascular Age-Related Macular Degeneration (AMD) |
| Key Mechanisms | Aflibercept (Eylea HD) is used to maintain vision and reduce treatment frequency. |
| Target Population | Patients with treatment-naive neovascular AMD. |
| Care Setting | Ophthalmology clinics and practices. |
Key Highlights
- Patients switching from 2 mg to 8 mg maintained vision and extended treatment intervals.
- No new safety signals were observed in the 8 mg group over 3 years.
- 80% of patients extended treatment intervals to 12 weeks or longer.
- Reduction in central subfield thickness and fluid was noted after switching to 8 mg.
- Approximately 40-50% of patients could extend treatment intervals beyond 20 weeks.
Guideline-Based Recommendations
Diagnosis
- Evaluate patients for neovascular AMD using standard diagnostic criteria.
Management
- Consider switching patients from 2 mg to 8 mg aflibercept for improved outcomes.
Monitoring & Follow-up
- Regularly assess visual acuity and retinal structure during treatment.
Risks
- Monitor for potential intraocular pressure changes and systemic safety signals.
Patient & Prescribing Data
Treatment-naive patients with neovascular AMD and those currently on 2 mg aflibercept.
Patients on 2 mg can switch to 8 mg to achieve better fluid reduction and extended treatment intervals.
Clinical Best Practices
- Offer 8 mg aflibercept as a first-line treatment for treatment-naive patients.
- Consider switching patients who have residual subretinal fluid or cannot be extended on 2 mg.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
